Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma

Stopped early · Phase 1

Conditions studied: Glioma, Glioblastoma, Glioblastoma Multiforme

In brief

It was previously shown that \[18F\]Fluorodopa (FDOPA) PET imaging results in intended management changes in 41% of brain tumor patients. However, its impact on patient outcome defined as survival, costs, and/or quality of life has not been demonstrated. Regulatory agencies require randomized trials to determine the impact of PET on patient management and outcome. In this study we hypothesize that the addition of FDOPA PET will improve patient outcome by more accurately identifying presence or absence of tumor recurrence than conventional imaging.

Key facts

Study ID

NCT02176720

Run by

The Methodist Hospital Research Institute

People needed

31

Starts

2014-05-01

Expected to finish

2016-03-01

Last updated by the study team

2018-08-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Suspected first recurrence of a glioblastoma tumor by clinical measures and/or MRI
• Age 18 and older

You may not qualify if…

• Breast feeding/ Pregnancy
• Severe psychiatric illness
• Primary diagnosis of a glioblastoma

Where it is running

• Houston Methodist Research Institute PET Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.